Titre : Fluphénazine

Fluphénazine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Drug Compounding
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Fluphénazine : Questions médicales les plus fréquentes", "headline": "Fluphénazine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Fluphénazine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-12", "dateModified": "2025-04-08", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Fluphénazine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Phénothiazines", "url": "https://questionsmedicales.fr/mesh/D010640", "about": { "@type": "MedicalCondition", "name": "Phénothiazines", "code": { "@type": "MedicalCode", "code": "D010640", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.300.783" } } }, "about": { "@type": "MedicalCondition", "name": "Fluphénazine", "alternateName": "Fluphenazine", "code": { "@type": "MedicalCode", "code": "D005476", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Diana Duarte", "url": "https://questionsmedicales.fr/author/Diana%20Duarte", "affiliation": { "@type": "Organization", "name": "OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, s/n, 4200-450 Porto, Portugal." } }, { "@type": "Person", "name": "Nuno Vale", "url": "https://questionsmedicales.fr/author/Nuno%20Vale", "affiliation": { "@type": "Organization", "name": "OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Doutor Plácido da Costa, s/n, 4200-450 Porto, Portugal." } }, { "@type": "Person", "name": "Michał Otręba", "url": "https://questionsmedicales.fr/author/Micha%C5%82%20Otr%C4%99ba", "affiliation": { "@type": "Organization", "name": "Department of Drug Technology, Medical University of Silesia, Katowice Faculty of Pharmaceutical Sciences in Sosnowiec, Sosnowiec, Poland." } }, { "@type": "Person", "name": "Leon Kośmider", "url": "https://questionsmedicales.fr/author/Leon%20Ko%C5%9Bmider", "affiliation": { "@type": "Organization", "name": "Department of General and Inorganic Chemistry, Medical University of Silesia, Katowice Faculty of Pharmaceutical Sciences in Sosnowiec, Sosnowiec, Poland." } }, { "@type": "Person", "name": "Aracely Miron-Ocampo", "url": "https://questionsmedicales.fr/author/Aracely%20Miron-Ocampo", "affiliation": { "@type": "Organization", "name": "Microbiology/Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Compounded medications for cardiovascular use in neonatology: an integrative review.", "datePublished": "2022-09-09", "url": "https://questionsmedicales.fr/article/36102396", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1590/1984-0462/2023/41/2021167" } }, { "@type": "ScholarlyArticle", "name": "Impact of Apparatus and Adapter on In vitro Drug Release of Ophthalmic Semisolid Drug Products.", "datePublished": "2023-09-07", "url": "https://questionsmedicales.fr/article/37679656", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s11095-023-03586-x" } }, { "@type": "ScholarlyArticle", "name": "Economic Considerations and Cost-Saving Strategies for Nonsterile Compounding Education.", "datePublished": "2023-07-16", "url": "https://questionsmedicales.fr/article/37454811", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajpe.2023.100571" } }, { "@type": "ScholarlyArticle", "name": "Advancing algorithmic drug product development: Recommendations for machine learning approaches in drug formulation.", "datePublished": "2023-08-09", "url": "https://questionsmedicales.fr/article/37562550", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ejps.2023.106562" } }, { "@type": "ScholarlyArticle", "name": "Accelerated Predictive Stability Study of a Pediatric Drug Product for a Supplemental New Drug Application.", "datePublished": "2024-06-06", "url": "https://questionsmedicales.fr/article/38844721", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1208/s12249-024-02848-0" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérocycliques 3 noyaux", "item": "https://questionsmedicales.fr/mesh/D006575" }, { "@type": "ListItem", "position": 5, "name": "Phénothiazines", "item": "https://questionsmedicales.fr/mesh/D010640" }, { "@type": "ListItem", "position": 6, "name": "Fluphénazine", "item": "https://questionsmedicales.fr/mesh/D005476" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Fluphénazine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Fluphénazine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-02", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Fluphénazine", "description": "Comment la fluphénazine est-elle diagnostiquée ?\nQuels tests sont utilisés pour évaluer son efficacité ?\nLa fluphénazine est-elle utilisée pour d'autres troubles ?\nQuels critères sont utilisés pour son diagnostic ?\nLa fluphénazine nécessite-t-elle un suivi médical ?", "url": "https://questionsmedicales.fr/mesh/D005476?mesh_terms=Drug+Compounding&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Fluphénazine", "description": "Quels sont les symptômes traités par la fluphénazine ?\nLa fluphénazine peut-elle aggraver certains symptômes ?\nQuels effets secondaires peuvent survenir ?\nComment reconnaître une réaction allergique à la fluphénazine ?\nLa fluphénazine affecte-t-elle l'humeur ?", "url": "https://questionsmedicales.fr/mesh/D005476?mesh_terms=Drug+Compounding&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Fluphénazine", "description": "Comment prévenir les effets secondaires de la fluphénazine ?\nDes mesures préventives sont-elles nécessaires avant le traitement ?\nLa fluphénazine nécessite-t-elle des précautions particulières ?\nComment éviter les interactions médicamenteuses ?\nLa prévention des rechutes est-elle possible avec la fluphénazine ?", "url": "https://questionsmedicales.fr/mesh/D005476?mesh_terms=Drug+Compounding&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Fluphénazine", "description": "Comment la fluphénazine est-elle administrée ?\nQuelle est la posologie habituelle de fluphénazine ?\nLa fluphénazine peut-elle être combinée avec d'autres médicaments ?\nQuels sont les objectifs du traitement avec fluphénazine ?\nY a-t-il des alternatives à la fluphénazine ?", "url": "https://questionsmedicales.fr/mesh/D005476?mesh_terms=Drug+Compounding&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Fluphénazine", "description": "Quelles complications peuvent survenir avec la fluphénazine ?\nComment gérer les complications liées à la fluphénazine ?\nLa fluphénazine peut-elle causer des problèmes cardiaques ?\nQuels signes indiquent une complication grave ?\nLes complications sont-elles fréquentes avec la fluphénazine ?", "url": "https://questionsmedicales.fr/mesh/D005476?mesh_terms=Drug+Compounding&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Fluphénazine", "description": "Quels sont les facteurs de risque pour la fluphénazine ?\nL'âge influence-t-il le risque d'effets secondaires ?\nY a-t-il des facteurs génétiques à considérer ?\nLe mode de vie affecte-t-il l'efficacité de la fluphénazine ?\nLes interactions médicamenteuses sont-elles un facteur de risque ?", "url": "https://questionsmedicales.fr/mesh/D005476?mesh_terms=Drug+Compounding&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment la fluphénazine est-elle diagnostiquée ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Elle est prescrite après évaluation clinique des symptômes psychotiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer son efficacité ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des évaluations psychologiques et des échelles de symptômes sont utilisées." } }, { "@type": "Question", "name": "La fluphénazine est-elle utilisée pour d'autres troubles ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être utilisée pour des troubles de l'humeur et des troubles comportementaux." } }, { "@type": "Question", "name": "Quels critères sont utilisés pour son diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les critères incluent la présence de symptômes psychotiques persistants." } }, { "@type": "Question", "name": "La fluphénazine nécessite-t-elle un suivi médical ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier est essentiel pour ajuster le traitement et surveiller les effets." } }, { "@type": "Question", "name": "Quels sont les symptômes traités par la fluphénazine ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Elle traite des symptômes tels que hallucinations, délires et agitation." } }, { "@type": "Question", "name": "La fluphénazine peut-elle aggraver certains symptômes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut parfois exacerber des symptômes chez certains patients." } }, { "@type": "Question", "name": "Quels effets secondaires peuvent survenir ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des effets comme la somnolence, la sécheresse buccale et des troubles moteurs peuvent apparaître." } }, { "@type": "Question", "name": "Comment reconnaître une réaction allergique à la fluphénazine ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées, démangeaisons ou gonflements peuvent indiquer une allergie." } }, { "@type": "Question", "name": "La fluphénazine affecte-t-elle l'humeur ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut influencer l'humeur, provoquant parfois dépression ou apathie." } }, { "@type": "Question", "name": "Comment prévenir les effets secondaires de la fluphénazine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier et une communication ouverte avec le médecin sont essentiels." } }, { "@type": "Question", "name": "Des mesures préventives sont-elles nécessaires avant le traitement ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une évaluation médicale complète est nécessaire avant de commencer le traitement." } }, { "@type": "Question", "name": "La fluphénazine nécessite-t-elle des précautions particulières ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des précautions sont nécessaires en cas de maladies cardiaques ou de troubles neurologiques." } }, { "@type": "Question", "name": "Comment éviter les interactions médicamenteuses ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Informez toujours votre médecin de tous les médicaments que vous prenez." } }, { "@type": "Question", "name": "La prévention des rechutes est-elle possible avec la fluphénazine ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un traitement continu et un suivi régulier peuvent aider à prévenir les rechutes." } }, { "@type": "Question", "name": "Comment la fluphénazine est-elle administrée ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elle est généralement administrée par voie orale ou par injection intramusculaire." } }, { "@type": "Question", "name": "Quelle est la posologie habituelle de fluphénazine ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La posologie varie, mais commence souvent à 2-5 mg par jour, ajustée selon les besoins." } }, { "@type": "Question", "name": "La fluphénazine peut-elle être combinée avec d'autres médicaments ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être utilisée avec d'autres antipsychotiques ou stabilisateurs de l'humeur." } }, { "@type": "Question", "name": "Quels sont les objectifs du traitement avec fluphénazine ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "L'objectif est de réduire les symptômes psychotiques et d'améliorer la qualité de vie." } }, { "@type": "Question", "name": "Y a-t-il des alternatives à la fluphénazine ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, d'autres antipsychotiques comme la rispéridone ou l'olanzapine peuvent être envisagés." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la fluphénazine ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications comme le syndrome extrapyramidal ou des troubles métaboliques peuvent survenir." } }, { "@type": "Question", "name": "Comment gérer les complications liées à la fluphénazine ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "La gestion inclut l'ajustement de la dose ou l'ajout de médicaments pour contrer les effets." } }, { "@type": "Question", "name": "La fluphénazine peut-elle causer des problèmes cardiaques ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut augmenter le risque de troubles du rythme cardiaque chez certains patients." } }, { "@type": "Question", "name": "Quels signes indiquent une complication grave ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des mouvements incontrôlés ou des changements de conscience doivent alerter." } }, { "@type": "Question", "name": "Les complications sont-elles fréquentes avec la fluphénazine ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les complications ne sont pas rares, mais leur fréquence varie selon les individus." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour la fluphénazine ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents de troubles psychotiques et les maladies neurologiques augmentent les risques." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'effets secondaires ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées sont plus susceptibles de développer des effets secondaires." } }, { "@type": "Question", "name": "Y a-t-il des facteurs génétiques à considérer ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des prédispositions génétiques peuvent influencer la réponse au traitement." } }, { "@type": "Question", "name": "Le mode de vie affecte-t-il l'efficacité de la fluphénazine ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des facteurs comme l'alimentation et l'exercice peuvent influencer son efficacité." } }, { "@type": "Question", "name": "Les interactions médicamenteuses sont-elles un facteur de risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines interactions peuvent augmenter le risque d'effets indésirables." } } ] } ] }

Sources (10000 au total)

Compounded medications for cardiovascular use in neonatology: an integrative review.

To analyze the profile of the compounded cardiovascular medicines prescribed in neonatology in Brazil.... An integrative bibliographic review was carried out, including studies published in the last 20 years. The used descriptors were: Intensive Care Neonatal, Off-Label Use, Pharmaceutical Preparations, i... The profile of routine prescrption in the neonatal unit was evaluated. The main cardiovascular medications prescribed as compounding formulation were: Spironolactone, Captopril, Furosemide, Hydrochlor... It was possible to analyze the profile of compounded cardiovascular medicines prescribed in neonatology in Brazil. The results showed the need for the development of medications suitable for the neona...

Impact of Apparatus and Adapter on In vitro Drug Release of Ophthalmic Semisolid Drug Products.

In vitro release testing (IVRT) is a widely used tool for evaluating the quality and performance of drug products. However, standardized sample adaptors or drug release apparatus setups for IVRT studi... Dexamethasone (DEX), a steroidal ingredient commonly used in ophthalmic drug products, was selected as a model drug. Ointments were prepared by mixing DEX in white petrolatum using a high shear mixer.... The sample adaptor setups had a minimal impact on cumulative drug release amount per area or release rate while USP IV apparatus with agitated flow enhanced drug release rates. The USP apparatus I wit... USP apparatuses and sample adaptors are critical considerations for IVRT. Two-sided semisolid adapter provides higher cumulative release, facilitating the discrimination between low drug content ophth...

Economic Considerations and Cost-Saving Strategies for Nonsterile Compounding Education.

To determine the economic considerations, including cost-saving strategies, associated with nonsterile compounding education for students in schools and colleges of pharmacy across the United States.... An electronic survey was sent to the American Association of Colleges of Pharmacy Pharmaceutics Section and Laboratory Instructor's Special Interest Group members. Quantitative and qualitative data we... Of 555 surveys sent, 46 were completed. Reported annual compounding budgets ranged from $3000 to $96,000. Reported annual equipment maintenance costs ranged from $400 to $18,000. Fifty percent of resp... Findings from this study may assist pharmacy administrators and course directors in evaluating the costs associated with nonsterile compounding education across the Academy and, more importantly, dete...

Magistral Compounding with 3D Printing: A Promising Way to Achieve Personalized Medicine.

Magistral compounding has always been an integral part of pharmacy practice. The increasing demand worldwide for personalized drug treatments might be accommodated by an increase in magistral compound... To investigate how 3D printing can be integrated into the existing compounding system by taking regulatory, economic, and profession-oriented aspects into account.... Semi-structured interviews were conducted with relevant Dutch stakeholders representing various health institutions, such as health ministries and boards, professional bodies, and different types of p... A total of 15 Dutch stakeholders were interviewed. It was found that the prevalence of compounding in community pharmacies in the Netherlands has decreased as a result of the practice shifting to spec... In the Netherlands, specialized compounding pharmacies have largely taken over compounding activities. 3D printing could be introduced within this system; however, challenges regarding how to regulate...